Skip to main content
. Author manuscript; available in PMC: 2017 May 15.
Published in final edited form as: Cancer Res. 2016 Feb 26;76(10):3045–3056. doi: 10.1158/0008-5472.CAN-15-2310

Figure 6. PEG-ADA or mAb TY/23 reduce radiation-induced lung fibrosis.

Figure 6

C57BL/6 mice irradiated with 0 Gy or 15 Gy WTI were treated with PBS, PEG-ADA (5 units) or mAb TY/23 (100 µg) twice weekly i.p. beginning at week 16. (A) Schematic depiction of the experimental setup. (B) Adenosine levels [nM] in BALF from WT mice at 25 weeks post-irradiation ± treatment with PEG-ADA (n = 6/6, 5/6). (C) CD73 enzyme activity in lungs of WT mice 25 weeks post-irradiation ± treatment with PEG-ADA or TY/23 (n = 9/9, 8/9, 3/6). (D) Ashcroft scores of WT mice ± PEG-ADA or TY/23 at 25 weeks post-irradiation (n = 7/7, 7/6, 3/5). Horizontal lines represent means. (E) MT or H&E stained lung sections from WT mice with PBS, PEG-ADA or TY/23 treatment at ≥ 25 weeks post irradiation. Asterisks emphasize thickening of alveolar wall structures and arrowheads fibrotic regions (scale bar = 100 µm). (F) qPCR analysis of fibronectin expression normalized to actin (n = 8/9, 7/9, 3/6) at ≥ 25 weeks post irradiation (mean ± SEM, B-D, F). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 by one-way ANOVA followed by post-hoc Newman-Keuls test (B, C, D, F).